Nash Pharmaceuticals Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease as well as 2 Additional Lead Targets
January 14, 2019 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
December 03, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease
November 13, 2018 07:00 ET
|
Breathtec Biomedical Inc.; Nash Pharmaceuticals Inc.
Planning Phase II Trial VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH)...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease
November 01, 2018 07:00 ET
|
Breathtec Biomedical Inc.
Planning Phase II Trial VANCOUVER, B.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
Breathtec Announces Closing of Private Placement
October 24, 2018 07:00 ET
|
Breathtec Biomedical Inc.
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical...
Breathtec Announces Acquisition of Nash Pharmaceuticals
October 22, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”) is pleased to announce...
Breathtec Announces Signing of Definitive Agreement to Acquire Nash Pharmaceuticals
October 09, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”) is pleased to announce...
Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.
August 02, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to announce that it will be...